
==== Front
JCI Insight
JCI Insight
JCI Insight
JCI Insight
2379-3708
American Society for Clinical Investigation

39133651
178767
10.1172/jci.insight.178767
Research Article
Enhancing radiotherapy response via intratumoral injection of a TLR9 agonist in autochthonous murine sarcomas
https://orcid.org/0000-0003-4962-3797
Su Chang Chang.Su@duke.edu
12
Kent Collin L. collin.kent@duke.edu
2
Pierpoint Matthew matthew.pierpoint@uhn.ca
2
Floyd Warren warren.floyd@duke.edu
3
Luo Lixia Lixia.luo@dm.duke.edu
2
Williams Nerissa T. Nerisnerissa.williams@duke.edu
2
Ma Yan yan.ma@duke.edu
2
Peng Brian brian.peng@duke.edu
2
https://orcid.org/0000-0003-0704-1529
Lazarides Alexander L. alexander.lazarides@gmail.com
2
https://orcid.org/0000-0001-7892-886X
Subramanian Ajay ajayss@stanford.edu
4
Himes Jonathon E. jon.himes@duke.edu
12
Perez Vincent M. vincent.perez@tempus.com
5
Hernansaiz-Ballesteros Rosa D. rosa.hernansaiz@tempus.com
5
Roche Kimberly E. kim.roche@tempus.com
56
Modliszewski Jennifer L. jenmod@unc.edu
67
Selitsky Sara R. sararselitsky@gmail.com
56
https://orcid.org/0000-0002-6808-9844
Shinohara Mari L. mari.shinohara@duke.edu
8910
https://orcid.org/0000-0002-6098-5353
Wisdom Amy J. amy.wisdom@duke.edu
11
Moding Everett J. emoding@stanford.edu
412
https://orcid.org/0000-0002-9839-2414
Mowery Yvonne M. yvonne.mowery@duke.edu
213
https://orcid.org/0000-0002-2086-205X
Kirsch David G. david.kirsch@uhn.ca
12141516
1 Department of Pharmacology and Cancer Biology and
2 Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
3 Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
4 Department of Radiation Oncology, Stanford University, Stanford, California, USA.
5 Tempus AI Inc., Durham, North Carolina, USA.
6 QuantBio LLC, Durham, North Carolina, USA.
7 Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
8 Department of Integrative Immunology,
9 Department of Molecular Genetics and Microbiology, and
10 Department of Neurobiology, Duke University School of Medicine, Durham, North Carolina, USA.
11 Harvard Radiation Oncology Program, Boston, Massachusetts, USA.
12 Stanford Cancer Institute, Stanford University, Stanford, California, USA.
13 Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
14 Department of Radiation Oncology and
15 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
16 Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Address correspondence to: David G. Kirsch, 610 University Ave., Toronto, Ontario M5G 2M9, Canada. Phone: 416.946.2094; Email: David.Kirsch@uhn.ca.
Authorship note: CS and CLK are co–first authors.

13 6 2024
22 7 2024
13 6 2024
9 14 e1787673 1 2024
11 6 2024
© 2024 Su et al.
2024
Su et al.
https://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
This article is available online at https://insight.jci.org/articles/view/178767
Radiation therapy (RT) is frequently used to treat cancers, including soft-tissue sarcomas. Prior studies established that the toll-like receptor 9 (TLR9) agonist cytosine-phosphate-guanine oligodeoxynucleotide (CpG) enhances the response to RT in transplanted tumors, but the mechanisms of this enhancement remain unclear. Here, we used CRISPR/Cas9 and the chemical carcinogen 3-methylcholanthrene (MCA) to generate autochthonous soft-tissue sarcomas with high tumor mutation burden. Treatment with a single fraction of 20 Gy RT and 2 doses of CpG significantly enhanced tumor response, which was abrogated by genetic or immunodepletion of CD8+ T cells. To characterize the immune response to CpG+RT, we performed bulk RNA-Seq, single-cell RNA-Seq, and mass cytometry. Sarcomas treated with 20 Gy and CpG demonstrated increased CD8 T cells expressing markers associated with activation and proliferation, such as Granzyme B, Ki-67, and IFN-γ. CpG+RT also upregulated antigen presentation pathways on myeloid cells. Furthermore, in sarcomas treated with CpG+RT, TCR clonality analysis suggests an increase in clonal T cell dominance. Collectively, these findings demonstrate that CpG+RT significantly delays tumor growth in a CD8 T cell–dependent manner. These results provide a strong rationale for clinical trials evaluating CpG or other TLR9 agonists with RT in patients with soft-tissue sarcoma.

Combining radiation therapy with TLR9 agonist CpG delays tumor growth in soft tissue sarcomas through a CD8+ T cell–dependent mechanism.

Immunology
Oncology
Cancer immunotherapy
Radiation therapy
T cells
National Cancer Institute https://doi.org/10.13039/100000054 7R35CA197616 National Cancer Institute https://doi.org/10.13039/100000054 F30CA268910 National Cancer Institute https://doi.org/10.13039/100000054 1R38CA245204 National Cancer Institute https://doi.org/10.13039/100000054 F30CA221268 Duke Cancer Institute https://doi.org/10.13039/100014228 P30CA14236 Varian Medical Systems https://doi.org/10.13039/100007210 283-3941 Duke Cancer Center Support GrantVarian provided funding but did not play a role in the design of this study or in analyzing the results.
==== Body
pmcIntroduction

Soft-tissue sarcomas (STS) are a heterogeneous group of malignancies (1). Following local therapies with surgery and radiotherapy, approximately 50% of patients with large, high-grade tumors develop distant metastasis. After metastases occur, limited therapeutic options are available, with median survival of approximately 12–18 months (2). Thus, there is a pressing need for alternative therapeutic approaches to improve overall survival for these patients.

Immunotherapy has recently emerged as a promising treatment for many solid tumors (3), with particularly high response rates in melanoma and non–small cell lung carcinoma (NSCLC). However, a phase II clinical trial in patients with advanced STS, SARC028, showed that only ~17.5% of patients responded to anti–PD-1 monotherapy, which suggests that sarcomas are more resistant to immune checkpoint blockade compared with 40%–45% objective response rates in patients with melanoma and NSCLC (4). Nevertheless, it should be noted that there are more than 50 histological subtypes for STS, each with its own distinct biological characteristics (5, 6). STS subtypes respond to various therapies differently. For instance, undifferentiated pleomorphic sarcoma (UPS) showed a more favorable response to pembrolizumab compared with other subtypes of sarcoma in SARC028 (4). Therefore, clinical trials of immunotherapy that enroll patients with multiple subtypes of sarcomas may underestimate the effect of immunotherapy in the most responsive subtypes of sarcoma.

Over 40 years ago, Stone and colleagues used a transplanted model of STS to discover that activating the immune system through bacterial infection can enhance tumor control when administered with radiation therapy (RT) (7). Many subsequent studies have suggested that RT can work synergistically with immunotherapy to suppress tumor growth (3, 8, 9). In this study, we found that the combination of CpG (unmethylated cytosine-phosphorothioate-guanosine forms of DNA), a TLR9 agonist, and RT suppresses tumor growth significantly using autochthonous mouse models of STS in which the tumor gradually develops under surveillance by an intact immune system (10, 11). Here, we show that CD8+ T cells are essential for mediating the antitumor effects of CpG and radiotherapy. We further demonstrate that depleting lymphocytes, especially CD8+ T cells, negate the treatment effects of CpG. Unlike immune checkpoint inhibitors that aim to reverse the exhaustion state of T cells, the TLR9 agonist CpG combined with RT draws CD8+ T cells expressing markers associated with activation and proliferation into the tumor. Taken together, these findings suggest a promising treatment option of combining TLR9 agonists and radiotherapy in treating patients with STS, a condition that often contains few T cells.

Results

CpG and RT suppress autochthonous p53/MCA sarcoma growth.

To investigate whether the combination treatment of CpG and RT improves tumor growth delay compared with single therapy with CpG alone or RT alone in a primary tumor model, we induced STS with a high mutational load in 129/SvJae mice by injecting an adenovirus-expressing CRISPR-Cas9, a single-guide RNA (sgRNA) targeting Trp53 (sgp53) (10), and the carcinogen 3-methylcholanthrene (MCA) into the gastrocnemius muscle (11) (Figure 1A). After tumor induction, primary sarcomas (p53/MCA model) develop at the injection site over 2–3 months under the selective pressure of immunoediting in immunocompetent mice (12). p53/MCA sarcomas demonstrate gross and histologic morphologies as well as transcriptional profiles similar to human UPS (10, 13). When tumor volumes reached 70–150 mm3, mice were randomized to receive 0 Gy or 20 Gy RT (Day 0 [D0]) and CpG or control (GpC dinucleotides with the positions of cytosine and guanine reversed relative to the phosphate linker) (D3 and D10) (Figure 1B). Significant tumor growth delay was observed with either CpG alone or RT alone compared with the control group. Mice treated with CpG and RT exhibited the longest time to tumor quintupling with a mean of 27.2 days compared with 8.3 days for mice treated with control, 11.9 days for CpG alone, and 20.6 days for radiotherapy alone, suggesting that the TLR9 agonist improves radiotherapy’s treatment effect in delaying tumor growth (Figure 1, C and D).

CyTOF demonstrates significantly increased activated CD8+ T cells in CpG+RT-treated tumors.

To begin to investigate if CpG is mediating growth delay by acting on immune cells rather than killing tumor cells directly, we performed an IncuCyte Live-Cell assay to monitor cell proliferation of 3 p53/MCA tumor cell lines after coincubation with titrated concentrations of CpG. The in vitro assay demonstrated that CpG does not directly inhibit the proliferation of p53/MCA tumor cell lines (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.178767DS1), indicating that in vivo tumor growth delay induced by CpG alone is not through direct tumor cell killing. To determine which cell populations play an important role in mediating the treatment effects of CpG and RT, we performed mass cytometry (CyTOF) on tumor cells and tumor-infiltrating immune cells (Figure 2A) (14). We induced p53/MCA tumors as described above and initiated treatment when tumors reached 180–300 mm3. We investigated the tumor immune microenvironment on D3 after CpG (D6 after RT) because we typically observed prominent tumor shrinkage at this time point in mice receiving combination therapy. Figure 2B shows a Uniform Manifold Approximation and Projection (UMAP) plot of CD45+ cells characterized by CyTOF for the 4 treatment groups. We observed significantly more CD8+ T cells in tumors from mice treated with CpG and RT (Figure 2C) compared with the other treatment groups, which was confirmed by CD8 IHC staining (Figure 2, D and E). These CD8+ T cells coexpressed Granzyme B and Ki-67 (R = 0.36, P ≤ 0.0001), indicating that these CD8+ T cells are not exhausted but rather are actively proliferating and primed for cytotoxic cell killing (Figure 2, F and G, and Supplemental Figure 2). CpG alone or RT alone does not increase CD8+ T cells significantly with CyTOF analysis, but RT alone does draw significantly more CD8+ T cells to the intratumoral area when compared with untreated tumors by IHC staining. Nevertheless, CpG+RT draws a significantly higher number of CD8+ T cells to the intratumoral area when compared with other treatment groups.

Single-cell RNA-Seq reveals changes in the adaptive immune system after CpG+RT combination therapy.

To identify the major transcriptional differences in immune cell populations with and without CpG and RT, we performed single-cell RNA-Seq (scRNA-Seq) on CD45+ tumor-infiltrating immune cells from an independent cohort of sarcomas sorted by FACS and harvested 6 days after 0 or 20 Gy RT and 3 days after Control or CpG (Figure 3A). After filtering and quality control, scRNA-Seq analysis generated data for 94,093 cells. Unbiased clustering using shared nearest neighbor (SNN) modularity optimization identified 20 cell clusters with distinct transcriptional profiles that were assigned to known cell lineages utilizing Seurat (15) (Supplemental Figure 3A). The predominant cell populations of intratumoral immune cells were myeloid cells, and this is consistent with previous scRNA-Seq analyses for primary p53/MCA sarcomas (12).

Since CD8+ T cells exhibited the most significant increase in cell numbers based on CyTOF, we subclustered T cells and NK cells to better identify transcriptional differences among sarcomas from the 4 treatment groups. Unsupervised clustering analysis resulted in the identification of 13 subpopulations. The 13 clusters were further annotated based on differentially expressed genes (DEGs) and canonical immune markers, including NK cells/innate lymphoid cells/NKT cells (c0 and c8), CD4+ T cells (c2, c9, and c10), Treg (c4), and CD8+ T cells (c1, c3, c5, c6, and c7) (Figure 3, B and C, and Supplemental Table 1). The most prominent difference across treatment groups was found in the CpG+RT treatment group with a higher number of activated CD8+ T cells (c1, c3, c5, c7) that express elevated levels of Granzyme B (Gzmb), Granzyme K (Gzmk), and IFN-γ (Ifng) (Figure 3, D and E; Supplemental Figure 3, B and C; and Supplemental Figures 4 and 5). Cell cycle distribution for these clusters is shown in Supplemental Figure 3D, which demonstrates that the majority of the CD8+ T cells are actively proliferating and not yet exhausted.

The majority of CD8+ T cells in the combination treatment group clustered to c1, c3, c5, and c7. Cluster c1 expresses high levels of Ccl5, Ly6c2, Cxcr6, Cd28, Gzmk, Ifng, Tnfaip3, and Tnfaip8 (Figure 3B and Supplemental Figure 3B). Ccl5 and Ly6c2 are highly associated with the maintenance and homing of memory T cells (16–18). Connolly and colleagues also identified a group of memory CD8+ T cells expressing high levels of Ccl5 and Ly6c2 in C57BL/6 mice that were infected with acute lymphocytic choriomeningitis virus (LCMV) (18). Cxcr6 is a marker for resident memory T cells and antitumor efficacy (19–21). Cd28, Gzmk, Ifng, Tnfaip3, and Tnfaip8 are activation markers. However, roughly half of the cells in c1 also express exhaustion markers such as Pdcd1 and Ctla4 (18, 22). Therefore, this population is likely a group of effector memory T cells, with some transitioning into early exhaustion. Furthermore, c3 is comprised of CD8+ T cells that express genes associated with cell proliferation, such as Mki67, Top2a, and Birc5 (23, 24) (Figure 3B and Supplemental Figure 3B), and it also expresses high levels of Runx3, Gzmb, with a small percentage of cells expressing Pdcd1 and Ctla4. Runx3 is a key regulator of tissue-resident memory CD8+ T cell differentiation and homeostasis, while the other genes are associated with effector and early exhaustion CD8+ T cells (25). Cluster c5 is another cluster of CD8+ T cells that also express high levels of Runx3, Cdca7, Stmn1, Txn1, Ifng, and granzyme-related genes (Figure 3B and Supplemental Figure 3B). These genes are associated with higher immune cell infiltration, as well as proliferative CD8+ T cells (26–30). However, about 50% of the cells in c5 also express inhibitory receptors and transcription factors such as Pdcd1 and Ctla4, which indicate that some of these cells are transitioning into an exhausted state (18). Cluster c7 expresses Ifng, Gzmk, Gzmb, and Ly6c2, suggesting that this cluster contains mostly effector memory T cells (31) (Figure 3B and Supplemental Figure 3B). Taken together, these data illustrate that there are increased effector/memory CD8+ T cells in the tumor after combination treatment with CpG and RT. In addition, these CD8+ T cells express relatively low levels of genes associated with exhaustion; usually less than 50% of T cells within a cluster express Pdcd1 and Ctla4, which are also usually upregulated in activated T cells. Other common genes associated with exhaustion, such as Lag3, Havcr2, and Tox, are hardly expressed in these intratumoral T cells (Supplemental Figure 3B) (22). These T cells are also highly proliferative, indicating that CpG+RT attracts CD8+ T cells, which are not yet exhausted, into the tumors.

The population sizes of NK/ILC/NKT cells (c0 and c8 expressing Ncr1), Tregs (c4 expressing Foxp3), γδT cells (c9 expressing Tcrg-C1), Th2 cells (c10 expressing Tbc1d4 and Tnfsf8), and a population of myeloid cells (c12 expressing Cd74 and H2-Aa) did not differ significantly between the 4 treatment groups (Figure 3B and Supplemental Figure 3, B and C) (30, 32–35). The 3 populations that were lower after CpG+RT compared with the control group are c2, c6, and c11 (Supplemental Figure 3C). Cluster c2 differentially expresses Cd4, Lef1, S1pr1, and Ccr7, which are genes generally associated with naive CD4+ T cells (36–40). Cluster c6 expresses Cd8a, Lef1, Ccr7, and Il7r, which are usually associated with naive CD8+ T cells (41). Cluster c11 is a cluster with very few cells that expresses Slamf6, Eomes, and Foxp1, which are often associated with exhausted or naive T cells (Figure 3B and Supplemental Figure 3B). Taken together, these data indicate that CpG+RT resulted in increased infiltration of CD8+ T cells, with these cells displaying a range of transcriptional profiles indicative of effector memory, proliferation, and early exhaustion states. However, naive CD4+ and CD8+ T cells were more abundant in untreated tumors, suggesting a shift in the immune landscape with CpG+RT. Both CpG-treated and CpG+RT-treated tumors express higher levels of Ifng and Gzmb when compared with control. Tumors treated with RT alone also express higher levels of Gzmb when compared with control. However, CpG+RT upregulated the transcription of CD8, Ifng, and Gzmk to a greater extent when compared with tumors in the other treatment groups (Supplemental Figures 4 and 5). This is consistent with the CyTOF and IHC staining results.

Bulk RNA-Seq demonstrated a similar increase in CD8+ T cells after CpG+RT treatment and specific T cell clonal expansion.

To gain insight into the overall transcriptional differences in the tumor and immune microenvironments, we performed bulk tumor RNA-Seq on an independent cohort of p53/MCA tumors harvested 6 days after RT and 3 days after CpG treatment or their respective controls. We then performed digital cytometry on the bulk tumor RNA-Seq data set using CIBERSORTx to estimate the abundance of 22 different immune cell populations in the tumor microenvironment (42). CIBERSORTx results from the bulk tumor RNA-Seq data set support the findings from CyTOF, CD8 IHC, and scRNA-Seq that CD8+ T cells increase significantly after treatment with CpG and RT (Figure 2C; Figure 3, D and E). These results from multiple orthogonal assays are consistent with the hypothesis that the superior treatment effect of combination treatment is mediated through influx, activation, and proliferation of CD8+ T cells.

Given that we observed activation and proliferation of CD8+ T cells, we next evaluated whether there was clonal T cell expansion. T cell receptor (TCR) clonality analysis was conducted on the bulk RNA-Seq data set and revealed that tumors treated with RT alone or CpG+RT have higher S-entropy scores, indicating increased infiltration of different clones of T cells into the tumor (Figure 4A). This is consistent with our findings of increased CD8+ T cells in tumors after combination therapy (Figures 2 and 3). TCR clonality assessment also demonstrated that sarcomas treated with combination treatment had a lower evenness score when compared with tumors receiving control treatment or CpG alone, possibly due to preferential tumor-antigen specific T cell expansion after treatment rather than pan–T cell proliferation (Figure 4B). It should be noted that CpG alone and RT alone also increase S-entropy and decrease evenness score for CD8+ T cells when compared with control. However, CpG+RT draws the most CD8+ T cells and, thus, attracts the highest number of tumor-antigen–specific T cells to the intratumoral area.

Petitprez and colleagues describe an immune-based classification (classes A–E) of STS based on the composition of the tumor microenvironment (43). Sarcoma immune classes (SIC) D and E are associated with improved survival, and SIC E is associated with a higher response rate to anti–PD-1 treatment. Using the bulk RNA-Seq, we assigned the murine p53/MCA tumors from each treatment group to an SIC based on the method described by Petitprez et al. (43) (Figure 4C). Mouse sarcomas treated with CpG and RT were all assigned to SIC D and E while sarcomas with no treatment were assigned to the less-inflamed SICs A, B, and C. Using CIBERSORTx and data from The Cancer Genome Atlas (TCGA), we compared the immune infiltration in human UPS samples from each SIC with murine p53/MCA tumors from each treatment group (Figure 4C). Similar to SIC D and E human tumors, mouse sarcomas treated with CpG and RT had the highest immune infiltration, further demonstrating the similarity between these tumors. It is interesting to note that even though mouse sarcomas treated with combination therapy closely resembled human SIC D and E tumors, in our experimental system, they did not respond to anti-PD1 treatment alone or in any combination with RT, CpG, and/or OX-40 agonist antibody (Supplemental Figure 6A). We included OX-40 because it was previously reported to act with CpG to stimulate the immune response in an autochthonous mouse model of breast cancer (44), but in our model system, OX40 was not active.

Combination treatment of CpG and radiotherapy promotes myeloid cell remodeling and upregulates expression of MHC-I and MHC-II.

We consistently observed an influx of CD8+ T cells in sarcomas treated with CpG and RT through CyTOF, scRNA-Seq, and bulk tumor RNA-Seq data. However, TLR9 is the canonical receptor for CpG, and it is constitutively expressed by B cells and plasmacytoid DCs rather than T cells. Therefore, we next used the CyTOF data to analyze TLR9-expressing antigen-presenting cells, as they could regulate the profound CD8+ T cell proliferation and trafficking into the tumor after CpG+RT. We observed that TLR9 protein expression is upregulated in RT alone and CpG+RT-treated tumors through CyTOF, especially in DCs and macrophages (Supplemental Figure 7A). We also observed upregulation of major histocompatibility complex (MHC) class I and class II proteins on antigen-presenting cells after treatment with CpG and RT through CyTOF (Figure 5A and Supplemental Figure 7A). A similar increase in intratumoral CD11c+ DCs was also observed with CpG+RT compared with control (Figure 5A and Supplemental Figure 7A). These results support the notion that an increase in DCs and proteins associated with antigen presentation pathways promotes the activation of CD8+ T cells after CpG+RT and, thus, enhances tumor killing. CIBERSORTx results also demonstrate expansions of M1 macrophages and activated DCs after combination treatment with CpG and RT (Figure 5B). It should be noted that RT seems to be the main driver for increased expression of TLR9, MHC-II, and CD11c. However, CpG+RT induced the most significant increase in MHC-I compared with control tumors, tumors treated with CpG alone, and tumors treated with RT alone; this corresponds with the most significant upregulation and activation of CD8+ T cells observed after CpG+RT combination therapy.

Unsupervised clustering analysis of DCs resulted in the identification of 7 subpopulations (Figure 5C), which we compared with publications for cell-type identification based on differential gene expression (Figure 5D, Supplemental Figure 8, and Supplemental Table 2). Cluster c0_0 is likely a group of proinflammatory conventional type 2 DCs (cDC2s) that express high Itgam, Il1b, Cd14, and Tnf, as previously identified by Cheng and colleagues (45). Cluster c0_1 closely resembles cDC1s with differential expression of Itgae, Xcr1, and Clec9a (45). CD103+ cDC1s have been shown to transport intact antigens to the tumor-draining lymph nodes and activate CD8+ T cells. Cluster c0_2 is characterized by increased expression of chemokine and IFN-inducible genes, such as Cxcl10, Ifit1, and Isg15, which were previously identified as cDC2_Isg15 (45).

Cluster c1 clustered farther apart from all other DCs and expresses signature genes representing plasmacytoid DCs (pDC), such as Siglech, Ly6c2, Bst2, Ptprcap, and Tcf4 (Figure 5D and Supplemental Figure 8) (46, 47). C3 resembles migratory DCs with high expression of Ccl5, Ccr7, Ccl22, and Cacnb3 (48–50). None of these populations had substantial changes in size based on treatment groups (Supplemental Figure 7B).

Cluster c2 is likely a population of monocyte-derived DCs that expresses Ctsk, which plays important roles in regulating DC maturation, enhancing DC–T cell interactions, and promoting TLR9-induced cytokine production (51–53). It is worth noting that c2 almost completely disappears after treatment with RT or CpG+RT (Supplemental Figure 7B). Since both bulk tumor RNA-Seq and CyTOF data demonstrate increased infiltration of DCs after combination treatment, it is plausible to hypothesize that c2 migrated to the lymph nodes for antigen presentation after CpG+RT. However, it is also possible that c2 was sensitive to radiation and was eliminated after treatment. Cluster c4 is another DC population that decreased after combination treatment (Figure 5D and Supplemental Figure 7B), and it expresses Itgam (CD11b) but not Itgae (CD103), which is the phenotype often associated with migratory cDCs that travel to lymph nodes for antigen presentation (54, 55).

To begin to investigate the role of myeloid cell populations in mediating treatment effects, we used the scRNA-Seq data to perform cell-cell communication analyses between myeloid cell populations and T cells (Supplemental Figure 9, A and B). Several intercell communication pathways changed after CpG+RT treatment. There is a high communication probability between THBS1–CD47 monocyte–T cells pair in the untreated tumors. After treatment with CpG+RT, there is less interaction between THBS1–CD47 (Supplemental Figure 9A). THBS1 is often found to be associated with tumor progression, metastasis, and therapy resistance in many different types of cancers (56–59). A recent study shows that monocytes are the primary source of THBS1 in colorectal cancer and that they contribute to the development of metastasis by inducing cytotoxic T cell exhaustion (56). After combination treatment with CpG and radiotherapy, new interactions between H2-k1–CD8a, H2-d1–CD8a, and CXCL4/9/10/16–CXCR3/6 were observed (Supplemental Figure 9A). Robust communications between H2-k1–CD8a/b1 and H2-d1–CD8a/b1 represent increased intratumoral antigen presentation by myeloid cell populations to T cells (60–62). Increased interactions between CXCL4/9/10/16–CXCR3/6 may promote the recruitment of T cells to the intratumoral area (19, 21, 63–67). These findings are consistent with a model where CpG+RT treatment promoted DC maturation by upregulating genes that are associated with antigen presentation, such as MHC-I and MHC-II. In summary, CellChat analysis indicates that the combination treatment induced upregulation of genes and cellular communications associated with antigen presentation and T cell trafficking.

Lymphocytes, especially CD8+ T cells, are crucial in mediating the antitumor effects of CpG and radiotherapy in vivo.

To evaluate whether the CpG+RT treatment effect is indeed mediated through the adaptive immune system in vivo, we induced p53/MCA tumors in Rag2–/–;γc– (male) or Rag2–/–;γc–/– (female) and their littermate controls Rag2+/–;γc+ (male) or Rag2+/–;γc+/– (female) (Figure 6A). Since the γc gene is X-linked, the genotypes for littermate controls are different between males and females. Rag2–/–;γc– (male) and Rag2–/–;γc–/– (female) mice are incapable of generating functional B cells, T cells, or NK cells. When tumor volume reached 70–150 mm3, mice were randomized to receive 0 Gy or 20 Gy RT (D0) and CpG or control (GpC dinucleotides with the positions of cytosine and guanine reversed relative to the phosphate linker) (D3 and D10) (Figure 6B). The increase in time to tumor quintupling with CpG+RT compared with control was similar for heterozygous littermate controls that retained functional B cells, T cells, or NK cells (Figure 6, C and D) and 129/SvJae mice (Figure 1C). However, this treatment effect of CpG+RT was lost in homozygous Rag2γc-double KO (Rag2γc-DKO) mice (Rag2–/–;γc– [male] and Rag2–/–;γc–/– [female]) (Figure 6, E and F), suggesting that the adaptive immune system plays a crucial role in facilitating the antitumor effects of adding CpG to RT.

We next directly tested if CD8+ T cells are necessary for the treatment effects observed with CpG+RT through CD8+ T cell depletion in 129/SvJae mice with p53/MCA sarcomas. When tumors reached 70–150 mm3, mice received i.p. injections of isotype control or anti-CD8 antibodies on the same day as RT or sham RT (Figure 7A). Isotype control or CD8-depleting antibodies are repeated every 3–4 days until euthanasia upon reaching the humane endpoint (Figure 7B). Tumor growth delay was observed with CpG+RT in the isotype control group (Figure 7, B and C), but the growth delay with combination treatment was not observed in the CD8-depleted mice (Figure 7, D and E). These results demonstrate the essential role of CD8+ T cells in tumor growth delay induced by CpG+RT in combination. Although TLR9 is the canonical receptor for CpG, it is possible that the effects of CpG are mediated through a different mechanism. Therefore, to investigate the role of TLR9 receptors in mediating the treatment effects of the combination of CpG+RT, we induced p53/MCA tumors in WT TLR9+/+ littermate controls and mice lacking 1 (TLR9+/– mice) or both (TLR9–/– mice) alleles for the TLR9 receptor (Supplemental Figure 10A). When tumor volume reached 70–150 mm3, mice were randomized to receive 20 Gy RT (D0) and CpG or control on D3 and D10 (Supplemental Figure 10A). TLR9–/– mice lost their sensitivity to the combination of CpG+RT (Supplemental Figure 10B). Interestingly, the response of p53/MCA sarcomas to CpG+RT was also diminished in TLR9+/– mice (Supplemental Figure 10C), suggesting that the level of TLR9 receptor plays a critical role in mediating the treatment response to CpG+RT (Supplemental Figure 10D).

Discussion

Many studies have explored synergistic effects between immunotherapies and RT in sarcoma (3, 8, 9). However, most preclinical experiments are conducted with xenograft or transplanted models in which the tumor does not coevolve with the host immune system. Therapeutic approaches that elicit impressive survival benefits in transplanted tumor models may fail when translated into clinical trials (12, 68, 69). In this study, we addressed the limitations of transplant tumor models by utilizing the high mutational load autochthonous p53/MCA murine sarcoma model, which allows the tumor to develop under the surveillance of an intact immune system (10, 11). p53/MCA sarcomas mimic the histology of human UPS, which is one of the more responsive sarcoma subtypes to immunotherapy treatments (4, 10, 13).However, the chemically induced p53/MCA sarcomas have a much greater number of nonsynonymous somatic mutations when compared with most human UPS (11, 70, 71). We have previously performed bulk tumor RNA-Seq on primary p53/MCA sarcomas and transplant p53/MCA sarcomas (12). CIBERSORTx analysis of the gene expression data from the 2 different murine tumor models was compared with human UPS samples from TCGA, and primary p53/MCA tumors resembled the less-inflamed sarcomas in patients with low immune infiltration and had a worse correlation with overall survival (12, 43). In contrast, untreated transplant p53/MCA tumors resembled highly inflamed human sarcomas with high levels of immune infiltrate and are associated with improved overall survival (12, 43).

Our results demonstrate an enhanced radiation response of primary sarcomas treated with intratumoral CpG as measured by tumor growth delay, which is mediated through the activation and expansion of intratumoral CD8+ T cells. Our work suggests that the combination of RT with a TLR9 agonist, such as CpG, warrants evaluation in a clinical trial of sarcomas and perhaps other cancers. Mechanistically, our work indicates that combination treatment with CpG and RT enhances the activation and proliferation of intratumoral CD8+ T cells, as demonstrated by CyTOF, IHC, scRNA-Seq, and bulk tumor RNA-Seq. These CD8+ T cells express high levels of granzymes and IFN-γ, indicating that they are activated and capable of cellular cytotoxicity. Furthermore, the majority of these T cells are also in the S or G2-M phases of the cell cycle, demonstrating active proliferation. The TCR clonality analysis further supports targeted tumor-antigen–specific T cell response rather than a general proliferation of T cells. Additionally, our findings show that p53/MCA sarcomas in mice treated with CpG and RT exhibit immune profiles similar to SIC classes D and E in patients with UPS and those classes are associated with better survival outcomes and response rates to anti-PD1 therapy in patients with STS. Furthermore, CD8+ T cell depletion in the murine model abrogated the treatment effect of CpG+RT, which establishes a critical role of CD8+ T cells in mediating the treatment effects of this combination therapy.

It should be noted that RT seems to be the main driver for the differential expression of TLR9, MHC-II, and CD11c in myeloid cells, while CpG is the main driver for Granzyme B expression in CD8 T cells. Although the expression of specific genes after combination CpG and RT treatment does not always differ significantly from tumors treated with CpG alone or RT alone, it is the combination of changes after RT, including increased TLR9 expression with the TLR9 agonist CpG, that is necessary for maximal CD8 T cell infiltration, which is required for maximal tumor response. Future functional studies are needed to determine the underlying mechanisms responsible for CD8+ T cell activation and trafficking to the tumor after CpG and RT that is distinct from CpG alone or RT alone. Sagiv-Barfi and colleagues explored the combined therapeutic effects of the administration of local TLR9 agonist with systemic anti-OX40 agonist in murine models with spontaneous mammary gland tumors (44). They observed significant tumor burden reduction not only at the TLR9 agonist injection site but also at distant tumor sites. They reported upregulated OX40 expression on CD4+ T cells after CpG treatment and superior treatment response when anti-OX40 was added to intratumoral CpG injections (44). However, we did not observe increased OX40 expression after CpG+RT (Supplemental Figure 6B), nor did we observe a synergistic treatment effect with anti-OX40 in the p53/MCA sarcoma model (Supplemental Figure 6A). Seo and colleagues recently published results from a phase I clinical trial utilizing intratumoral injection of a TLR4 agonist and radiotherapy to treat 12 patients with metastatic sarcoma (72). They observed significantly elevated intratumoral infiltration of CD4+ T cells and tumor-antigen–specific clonal expansion of this population (72). In contrast, in the p53/MCA model, we did not observe substantial changes in the intratumoral CD4+ T cell population after combination of CpG+RT, suggesting potential differences in immune-activation mechanisms between TLR4 and TLR9 pathways (Figure 3E and Figure 5B) and/or differences in the mouse model and human sarcomas.

There were some differences in the cell population changes after CpG+RT treatment in scRNA-Seq data versus bulk tumor RNA-Seq and those differences might stem from different rates of mRNA recovery in the sample preparation process. For example, both bulk tumor RNA-Seq and CyTOF data demonstrate an increase in DC populations after combination treatment with CpG+RT. However, scRNA-Seq generally showed a decrease in the number of infiltrating DCs after combination treatment, suggesting a technical limitation for detecting DCs with scRNA-Seq in our experiments. 10X Genomics reported that about 30%–32% of mRNA transcripts are captured per cell utilizing the Single Cell 3′ reagent chemistry v3 (73). However, Qiagen reports more than 90% mRNA recovery from tissues utilizing their mRNA extraction kit (74). Therefore, differences in mRNA recovery could partly account for discrepancies in DC populations observed between bulk tumor RNA-Seq and scRNA-Seq data.

Overall, CpG appears to be an excellent candidate for the treatment of patients with STS due to its ease of local administration and favorable safety profile (75, 76). No apparent toxicity was observed in mice treated with CpG+RT. Furthermore, our in vivo studies with p53/MCA sarcomas demonstrated that using TLR9 agonists in conjunction with radiotherapy significantly outperformed the individual treatments or no treatment in terms of delaying tumor progression. As previously mentioned, Seo and colleagues recently demonstrated that metastatic sarcoma lesions treated with the combination therapy of TLR4 agonist and radiotherapy achieved durable local control (72). Similarly, our in vivo studies in mice with p53/MCA sarcomas demonstrated that intratumoral injection of CpG as a TLR9 agonist in conjunction with radiotherapy significantly improved response compared with either treatment alone as measured by tumor growth delay. Our results with CpG+RT and the initial clinical trial of a TLR4 agonist with RT demonstrate the potential effectiveness of TLR agonists and radiotherapy in treating sarcomas. Furthermore, unlike other immunotherapies, such as immune checkpoint inhibitors that aim to reverse the exhaustion state of T cells, TLR9 agonist combined with RT causes activated CD8+ T cells that are not yet exhausted to infiltrate the tumor and enhance the radiation response. This study supports translating the therapeutic approach of radiotherapy with CpG or another TLR9 agonist into clinical trials for patients with STS.

Methods

Sex as a biological variable

These studies included both male and female animals.

Experimental models details

The Rag2–/–;γc–/– mice, TLR9–/– mice, and their littermates were purchased from The Jackson Laboratory and bred at Duke University with a mixed BALB/cAnNTac and 129S4/SvJae background. WT 129S4/SvJae mice used in this study were also purchased from The Jackson Laboratory and bred at Duke University. To minimize the effects of sex and genetic background, male and female mice and age-matched littermate controls were used for every experiment so that potential genetic modifiers would be randomly distributed between experimental and control groups.

Sarcoma induction and treatment

Primary p53/MCA sarcomas were generated in 129S4/SvJae, Rag2–/–;γc–/–, TLR9–/–, and littermate control mice between 6 and 12 weeks old by intramuscular injection of adenovirus expressing Cas9 and sgRNA targeting Trp53 (Adeno-p53-sgRNA; Viraquest) into mice as previously described (12). Ddenovirus (25 μL) was mixed with 600 μL DMEM (Thermo Fisher Scientific) and 3 μL 2M CaCl2, and it was then incubated for 15 minutes at room temperature prior to injection. The prepared mixture (50 μL) was injected into the gastrocnemius muscle, followed by injection of 300 μg MCA (MilliporeSigma) resuspended in sesame oil (MilliporeSigma) at 6 μg/μL.

For tumor growth delay studies in 129S4/SvJae, Rag2–/–;γc–/–,TLR9–/–, and littermate control mice, the mice were randomized to treatment groups when tumors reached 70–150 mm3 (D0). Tumors were monitored 3 times weekly by caliper measurements in 2 dimensions until 1 dimension of the tumor reached 15 mm. Mice received 1 dose of 0 or 20 Gy of image-guided RT to the tumor-bearing hind limb on D0. Mice were anesthetized with 2% isoflurane and 98% oxygen at 2 L/min and held on the specimen positioning stage of a μCT on a Small Animal Radiation Research Platform. The first half of tumor quintupling studies and scRNA-Seq and bulk tumor RNA-Seq experiments were conducted utilizing SmART+, Precision Inc. The second half of tumor quintupling studies and CyTOF experiments were conducted using SARRP, Xstrahl Inc. The right hind limb was identified using μCT guided fluoroscopy (60 kVp, 0.8 mA x-rays using a 1 mm Al filter). Irradiations were performed using parallel-opposed anterior and posterior x-rays, which were delivered via 20 mm × 20 mm collimators (220 kVp, 13 mA x-rays using a 0.15 mm Cu filter) with a dose of 20 Gy of radiation prescribed to mid-plane delivered in a single, unfractionated dose.

In total, 50 μL of CpG or GpC control was injected intra- and peritumorally on D3 and D10. CpG (InvivoGen, ODN 1826) or GpC control with the positions of cytosine and guanine reversed relative to the phosphate linker (InvivoGen, ODN 2138) was diluted in endotoxin-free water at 1 mg/mL. Antibodies were administered starting on D0 (on the same day as RT) by i.p. injection of 200 μL per dose at 1 mg/mL diluted in PBS. Anti-CD8 (BioXCell, BE0061) or isotype control (BioXCell, BE0090) antibodies were injected every 3–4 days for the duration of the experiment. Anti–PD-1 (BioXCell, BE0146) and isotype control (BioXCell, BE0089) were injected on D3, D7, and D10. Anti-OX40 (Bristol Myers Squibb) or isotype control (Bristol Myers Squibb) were injected on D3 and D10.

Mass cytometry

Tumor harvest and dissociation.

Tumors were dissected from mice, minced, and digested using the Miltenyi Biotec tumor dissociation kit (mouse, tough tumor dissociation protocol) for 40 minutes at 37°C. Cells were then strained through a 70 μm filter and washed with Maxpar Cell Staining Buffer (CSB) (Standard Bio Tools). RBCs were lysed using ACK lysis buffer (Lonza). Cells were then washed and resuspended in Maxpar PBS for cell counting using Trypan Blue (Thermo Fisher Scientific).

CyTOF Staining.

For custom-conjugated antibodies, 100 μg of antibody was coupled to Maxpar X8 metal-labeled polymer according to the manufacturer’s protocol (Standard Bio Tools). After conjugation, the metal-labeled antibodies were diluted in Antibody Stabilizer PBS (Candor Bioscience) for long-term storage according to the manufacturer’s protocol. After tumor dissociation and RBC lysis as described above, 3 million cells per sample were transferred to 5 mL round-bottom tubes (Corning). Cells were incubated with 300 μL of Cell-ID Cisplatin-195Pt (Standard Bio Tools) diluted 1:8,000 in Maxpar PBS (Standard Bio Tools) for 5 minutes at room temperature before being washed with CSB (Standard Bio Tools). Samples were incubated with 1.5 μg TruStain FcX PLUS Blocking Reagent (BioLegend) for 10 minutes at room temperature; then, 56.55 μL extracellular antibody cocktail was added and incubated for 30 minutes at room temperature. The final staining volume was 130 μL, including residual CSB from the wash, FcX PLUS blocking reagent, CSB, and antibody cocktail. Cells were washed twice with CSB and were then fixed and permeabilized with Foxp3/Transcription Factor Fixation/Permeabilization Buffer (eBioscience) overnight at 4°C. The next morning, cells were washed twice with permeabilization buffer (eBioscience). In total, 50 μL of intracellular antibody cocktail in permeabilization buffer was added and incubated for 30 minutes at room temperature, followed by 2 washes with permeabilization buffer. Cells were fixed in 1.6% methanol-free paraformaldehyde (PFA) (Thermo Fisher Scientific) diluted with Maxpar PBS (Standard Bio Tools) for 10 minutes at room temperature. Samples were incubated for 1 hour in Maxpar Fix and Perm Buffer (Standard Bio Tools) with 1 mL of 157.2 nM Cell-ID Intercalator (Standard Bio Tools) containing 191Ir and 193Ir. After staining, samples were centrifuged (at 800 g for 5 minutes) and resuspended in 100 μL of residual Intercalator/Fix and Perm Buffer. Cells were transferred to 1.5 mL microcentrifuge tubes and stored at –80°C. On the day of acquisition, cells were washed once with CSB and once with Cell Acquisition Solution (CAS) (Standard Bio Tools) before being filtered and diluted in CAS containing 10% EQ Calibration Beads (Standard Bio Tools) at 0.5 million cells per mL before acquisition on a mass cytometer (Helios).

CyTOF data analysis.

Mass cytometry data were analyzed using Standard Bio Tools CyTOF software (v7.0). Individual samples were gated in Cytobank to exclude beads, debris, dead cells, and doublets for further analysis. For each experimental group (treatment), cells from 8 to 11 tumors per group were manually gated to identify specific populations.

CyTOF dimension reduction and clustering.

Expression data from all .fcs files were log2 transformed. We used unbiased clustering with FastPG v0.0.8 to identify clusters of cells in the expression data (77). A k of 50 was used, and all cells were included (CD45hi and CD45lo) in the clustering step. Dimension reduction was performed on the log2 expression data using both PCA and UMAP approaches. The statistical significance of markers across treatment groups was determined using a Wilcoxon rank-sum test.

Bulk tumor RNA-Seq of p53/MCA sarcomas in 129S4/SvJae mice

RNA extractions.

Tumor specimens and matched muscle control were harvested and stored in RNALater (Ambion) at −80°C until all samples were collected. RNA extractions from each sample were performed using RNeasy Fibrous Tissue Mini Kit (Qiagen). Extracted total RNA quality and concentration were assessed on a NanoDrop Spectrophomoter (Thermo Fisher Scientific). RNA-Seq libraries were prepared using TruSeq Small RNA Library Preparation Kits (Illumina) following the manufacturer’s protocol. RNA-Seq was performed on an Illumina Novoseq in 151 base pair, paired-end configuration. Greater than 50,000 reads per cell were collected per the manufacturer’s recommendation.

Sequence alignment and SIC labels.

All FASTQ files were processed using a combination of STAR v2.7.10a and Salmon v1.2.0 and were aligned with mouse build GRCh38 - mm10, release 84, as a reference. GENCODE vM10 was used for transcriptome annotation (78, 79). FASTQ files from the same sample but different lanes were merged. Reads were mapped using STAR v2.7.10a. Transcripts were counted with Salmon v1.2.0 and Picard v 2.27.4 was utilized for quality control (80). Mouse genes were mapped to their corresponding human orthologs using the ‘biomaRt’ R package (81). The expression matrix was restricted to protein-coding genes, and expression levels per gene were summarized as transcripts per million (TPM). Preprocessed bulk RNA-Seq profiles from human UPS from TCGA were downloaded and scaled to TPM. SIC labels were obtained from the authors (43, 71).

CIBERSORTx RNA-Seq analysis.

Cell type proportions were inferred using CIBERSORTx with 2 previously published signature matrices (LM22 and TR4) (42). LM22 encompasses 22 distinct human immune cell subsets, and TR4 comprises epithelial, fibroblast, endothelial, and immune cells (42, 82). Bar plots and heatmaps were visualized with the ggplot2 and ComplexHeatmap R packages, respectively (83). For the heatmaps, abundances were normalized to mean zero and unit variance. P values were calculated using 2-sided Wilcoxon tests.

Assignment of mouse sarcomas to SIC.

SIC were assigned to normal muscle and mouse sarcomas in each treatment group as described previously (43). Briefly, abundance scores for T cells, CD8 T cells, cytotoxic lymphocytes, B cell lineage, NK cells, monocytic lineage, myeloid DCs, neutrophils, and endothelial cells were determined from the bulk RNA-Seq using MCP-counter (84) and normalized across samples. Because the transcriptional profiles of the mouse tumors in this study are most similar to human UPS, we constructed centroids using the MCP-counter Z scores for UPS from TCGA (71) based on the SIC labels obtained from the authors (43). Mouse samples were assigned to the closest SIC by evaluating the Euclidean distance to each centroid.

TCR reconstruction and CDR3 metrics.

TRUST4 v1.0.12 (Tcr Repertoire Utilities for Solid Tissue) were used to reconstruct TCR and BCR sequences from BAM files generated from the STAR/Salmon outputs (85). All parameters for TRUST4 were set to default. The final output from TRUST4 was summary matrices for each sample that included hypervariable complementarity-determining region 3 (CDR3) nucleotide and amino acid sequences, counts, frequencies, and V, D, and J chain names. Using the outputs from TRUST4, we calculated the following diversity metrics for all CDR3 species per treatment group: Shannon entropy and evenness by sequence were used to compare TCR species across treatment groups (86, 87). Shannon entropy measures the richness and abundance of each species. Species evenness measures the uniformity of the species. The calculations for each metric given a single TCR species are as follows:

Count proportion: species count / total species count

Species richness: nucleotide length

Shannon entropy: –Σ (count proportion × log[count proportion])

Evenness by sequence: Shannon entropy / log(species richness)

scRNA-Seq of p53/MCA sarcomas in 129S4/SvJae mice

Tumor harvest and dissociation.

Tumors were dissected from mice, minced, and digested using the Miltenyi Biotec tumor dissociation kit (mouse, tough tumor dissociation protocol) for 40 minutes at 37°C. Cells were then strained through a 70 μm filter and washed with FACS buffer (HBSS [Thermo Fisher Scientific] with 5 mM EDTA [Sigma-Aldrich] and 2.5% FBS [Thermo Fisher Scientific]). RBCs were lysed using ACK lysis buffer (Lonza) and washed again with FACS buffer.

FACS.

Dissociated cells were prepared for FACS of CD45+ cells for scRNA-Seq. Single-cell suspensions of tumor tissues were blocked with 1.5 μg TruStain FcX PLUS Blocking Reagent (BioLegend) for 10 minutes at room temperature before being stained with Live/Dead dye (Zombie Aqua, BioLegend) and anti–mouse CD45 (APC-Cy7, BioLegend) for 25 minutes on ice. Live CD45+ cells were isolated for scRNA-Seq using an Astrios (Beckman Coulter) sorter and resuspended in PBS with 0.04% BSA at a concentration of 1,000 cells/μL for scRNA-Seq.

Library preparation and sequencing.

Single-cell suspensions from sorted live CD45+ cells were loaded on a Chromium Controller (10X Genomics) to generate single-cell beads in emulsion, and scRNA-Seq libraries were prepared using the Chromium Single Cell 3′ Reagent Kits (v3.1 Single Index Kit), Chromium Next GEM Single Cell 3′ GEM, Library & Gel Bead Kit v3.1, Chromium Next GEM Chip G Single Cell Kit, and Single Index Kit T Set A (10X Genomics) following the manufacturer’s protocol. Single-cell barcoded cDNA libraries were qualified and quantified using Agilent Bioanalyzer. cDNA libraries were sequenced on an Illumina NextSeq 500. Read lengths were 26 bp for read 1, 8 bp for i7 index, and 98 bp for read 2. Ten thousand cells from each sample were sequenced with greater than 50,000 reads per cell as recommended by the manufacturer.

Analysis of scRNA-Seq data.

Raw FASTQ files were mapped to Mus musculus reference mm10 GRCm38 using CellRanger v6.1.1 (10X Genomics) with default parameters and GENCODE vM23 for transcriptome annotation. Expression matrix assembly and calculation of cell metrics (gene counts, molecule counts, percent mitochondrial genes) were performed using Seurat v.4.1.0 (88). We removed low-quality cells that had total nonzero gene counts ≤ 500 and ≥ 5,000; total nonzero molecule counts ≤ 2,000 and ≥ 40,000; ≥ 10% mitochondrial gene presence; a hybrid doublet score ≥ 1.0 per SCDS default parameters (89); and an ambient RNA contamination score ≥ 0.50 per decontamX default parameters (90). Count data were normalized using LogNormalize in Seurat with a scaling factor of 10,000. The top 10,000 variable features were then used to scale the data using Seurat’s ScaleData function. Although cell cycle genes were scored using CellCycleScoring in Seurat, no variables were regressed out upon scaling. Cell types were annotated using SingleR v.1.8.1 and the mouse immunological genome project data set (Immgen) available in the celldex v.1.4.0 library as a reference (91). Dimension reduction was performed using Harmony v0.1.0 with RunHarmony set to theta of 2 and all other parameters set to default (92). Harmony reductions were used for all downstream UMAP and clustering calculations. To select a clustering resolution, we calculated the adjusted rand index (ARI) and selected the clustering resolution with the highest ARI. Additional subclustering was performed downstream on cell types individually, and T cell subtypes were annotated using the T cell atlas from projecTILs with filter.cells set to “TRUE” (93). DEGs were identified using the FindAllMarkers in Seurat with only.pos set to TRUE, logfc.threshold set to 0.1, and min.pct set to 0.25.

IHC staining

Parts of the sarcoma were preserved for IHC staining when tumors were harvested for bulk tumor RNA-Seq. Small chunks of sarcoma were fixed in 10% formaldehyde overnight and then preserved in 70% ethanol until paraffin embedding. Formalin-fixed, paraffin-embedded tissues were sectioned and fixed onto slides for staining. Tissue sections were then deparaffinated by xylene and rehydrated with a series of graded ethanol and tap water. Slides were cooked in a rice cooker with Antigen Unmasking Solution, Citric Acid Based (Vector Laboratories) for epitope retrieval. After washes with tap water and PBS, tumor sections were incubated in normal goat serum for 30 minutes at room temperature and then with CD8 antibody (Cell Signaling Technology, 98941) at 4°C overnight. The following day, slides were washed with PBS and then incubated with biotinylated anti-rabbit antibody (BA-1000-1.5, Vector Laboratories) for 30 minutes at room temperature. VECTASTAIN ELITE ABC-HRP Reagent (Vector Laboratories) was then added to tumor sections for another 30 minutes at room temperature. Mayer’s hematoxylin (Sigma-Aldrich) was applied to the slides for counter-staining. Tumor slides were dehydrated and sealed with coverslips. Ten fields per tumor slide were randomly selected and counted by an observer blinded to treatment at 40× magnification for the number of CD8+ T cells.

Reagent information

See Supplemental Table 3 for antibody clones, catalog numbers, and mouse strains.

Statistics

Experiments were designed such that littermate controls were used for all experiments. For bar graphs, all data are presented as mean ± SEM. For comparison of time to tumor quintupling in tumor growth experiments, we performed a Kruskal-Wallis test (after all groups failed the Kolmogorow-Smirnov test for normality) on the time to tumor quintupling (days) for each sample stratified by treatment group. To identify differences between groups, we performed a pairwise Wilcoxon test. P ≤ 0.05 was considered significant. This was complemented by a Kaplan-Meier curve and a log-rank test to compare survival without tumor quintupling across treatment groups.

Study approval

All animal studies were performed in accordance with protocols approved by the Duke University IACUC and adhered to the Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011).

Data availability

All sequencing data generated for this manuscript have been deposited in publicly accessible databases. The p53/MCA bulk tumor RNA-Seq data generated in this study are available in the NCBI Gene Expression Omnibus (GEO) database under the accession no. GSE252213. The p53/MCA scRNA-Seq data generated in this study are available in the NCBI Gene Expression Omnibus (GEO) database under the accession no. GSE252143. The mass cytometry data generated in this study are available in the flowrepository.org database under the ID code FR-FCM-Z74J. Code for scRNA-Seq analysis in the manuscript can be found at https://github.com/DukeChangSu/CpG-RT-single-cell-RNAseq-analysis-code (commit ID = 6d3d671). Values for all data points in graphs are reported in the Supporting Data Values file. Source data are provided with the paper.

Author contributions

CS and DGK conceptualized the project. CS, CLK, AJW, EJM, YMM, and DGK developed the methodology. CS, CLK, AS, VMP, RDHB, KER, JLM, SRS, and EJM conducted statistical analysis. CS, CLK, MP, LL, NTW, YM, WF, BP, ALL, and JEH performed the investigation. CS and DGK wrote the original draft of the manuscript. CS, AS, VMP, MLS, AJW, EJM, YMM, MP, and DGK reviewed and edited the manuscript. CS was responsible for visualization. DGK supervised the project. CS and CLK are co–first authors. CS is listed first due to her writing contributions.

Supplementary Material

Supplemental data

Supplemental table 1

Supplemental table 2

Supplemental table 3

Supporting data values

We thank Malay Haldar for advice on defining mouse DC populations. We thank Andrea Daniel for suggestions in experimental design. We thank Marie Iannone at the University of North Carolina Mass Cytometry Core for running CyTOF samples. We thank Azucena Gomez-Cabrero for her assistance with designing the CyTOF panel. Graphics for schematics were created using Biorender.com. We thank Bristol Myers Squibb for providing the anti-OX40 antibody. This work was supported by the NCI with grants 7R35CA197616 to DGK; F30CA268910 to CS; 1R38CA245204 to CLK; F30CA221268 to AJW; NIAID R01AI160737 to MLS; and P30CA14236, University Cancer Research Fund (UCRF) from P30CA014236 the Duke Cancer Center Support Grant, and P30CA016086, the UNC Cancer Center Core Support Grant. Funding for this work was also provided by Varian Medical Systems, but Varian did not play a role in the design of this study or in analyzing the results.

Version 1 07/22/2024

Electronic publication

Figure 1 Increased tumor growth delay after treatment with CpG ODN and radiation therapy in autochthonous p53/MCA sarcomas.

(A) Primary sarcoma initiation by intramuscular injection of Adeno-Cas9-sgp53 and MCA. (B)Autochthonous sarcomas develop at the injection site about 7–11 weeks after injection. Mice were treated with CpG ODN or control GpC dinucleotides and 0 or 20 Gy when tumors reached > 70 mm3. (C) Mice with p53/MCA sarcomas received control GpC dinucleotides with 0 Gy (black, n = 26), CpG ODN alone (green, n = 23), control GpC dinucleotides with 20 Gy (blue, n = 21), or CpG ODN with 20 Gy (red, n = 20). Time to tumor quintupling (days) after the indicated treatment. (D) Mice with p53/MCA sarcomas received control GpC dinucleotides with 0 Gy (black, n = 26), CpG ODN alone (green, n = 23), control GpC dinucleotides with 20 Gy (blue, n = 21), or CpG ODN with 20 Gy (red, n = 20). Kaplan-Meier analysis with tumor quintupling as the endpoint. Kruskal-Wallis test was used for comparison across the groups, while the Wilcoxon test was selected for the pair-wise comparisons. **P ≤ 0.01, ****P ≤ 0.0001.

Figure 2 CyTOF and IHC staining demonstrates enhanced intratumoral infiltration of activated CD8 T cells after combination treatment.

(A) Treatment schedule and tumor processing schematic. (B) UMAP plot of CyTOF data clustering for all CD45hi cells from all tumors and treatment groups. (C) Frequency of CD8+ cells/live CD45+ cells by CyTOF. Data show mean ± SEM, analyzed by 3-way ANOVA. (D) Average number of CD8+ cells/0.2 mm2 in IHC slides.(E)Representative IHC staining with CD8 Ab. Scale bar: 100 μm. (F) CD8 expression in CyTOF CD45 high UMAP plot. (G) Granzyme B expression in CyTOF CD45hi UMAP plot. *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001.

Figure 3 scRNA-Seq shows increased CD8 T cell infiltration into the tumor after CpG+RT.

(A) Treatment schedule and tumor processing schematic. (B) Bubble plot of top 3 differentially expressed genes in each of the T cell subclusters. The shades of color are correlated with levels of expression. The sizes of circles are correlated with percentage of cells in that cluster that express the gene of interest. (C) UMAP plot of T cell and NK cell scRNA-Seq subclustering. (D) UMAP plot of T cell and NK cell subclustering colored by treatment groups.(E) UMAP plot of lymphocytes subclustering colored by CD4 (red), CD8 (blue), NK/ILC (black), and γδT (yellow) cells. Mice with p53/MCA sarcomas received control GpC dinucleotides with 0 Gy (n = 5), CpG ODN alone (n = 5), control GpC dinucleotides with 20 Gy (n = 5), or CpG ODN with 20 Gy (n = 5).

Figure 4 Treatment with CpG+RT promotes tumor-antigen–specific clonal expansion of T cells and tumor immune microenvironment remodeling.

(A) p53/MCA sarcoma develops at the injection site about 7–11 weeks after induction. Mice were treated with CpG ODN or GpC dinulcotides control and 0 or 20 Gy when tumors reached > 180 mm3. Sarcomas received control GpC dinucleotides with 0 Gy (n = 5), CpG ODN alone (n = 5), control GpC dinucleotides with 20 Gy (n = 5), or CpG ODN with 20 Gy (n = 5). Shannon entropy calculated from the abundance of TCR sequences captured by TCR sequencing and stratified by treatment group. Increasing entropy indicates reduced uniformity of TCR sequences. P values were calculated using 2-sided Wilcoxon tests. (B) TCR evenness is Shannon entropy normalized by species richness. (C) Immune-based classification of murine primary sarcomas. Sample sizes: muscle control (n = 3), tumor control (n = 5), CpG (n = 5), RT (n = 5), CpG+RT (n = 5).

Figure 5 Treatment with CpG+RT promotes intratumoral myeloid cell remodeling.

(A) UMAP plot of CyTOF clustering for CD45hi cells from control (GpC dinucleotides) and CpG+RT treatment groups. MHC-I, MHC-II, and CD11c expression are highlighted in red. (B) Immune cell composition of all treatment groups from Bulk RNA-Seq. (C) UMAP plot of DC subclustering. (D) Bubble plot of top 3 differentially expressed genes in each of the DC subclusters. The shades of color are correlated with levels of expression. The sizes of circles are correlated with percentage of cells in that cluster that express the gene of interest. Sample sizes: tumor control (n = 5), CpG (n = 5), RT (n = 5), CpG+RT (n = 5).

Figure 6 Lymphocytes mediate the antitumor effects of the combination treatment CpG+RT.

(A) Primary sarcoma initiation by intramuscular injection of Adeno-Cas9-sgp53 and MCA. (B) Autochthonous sarcoma develops at the injection site about 7–11 weeks after induction. Mice were treated with CpG ODN or control GpC dinucleotides and 0 or 20 Gy when tumors reached > 70 mm3. (C) Heterozygous mice (Rag2+/–;yc+ or Rag2+/–;yc+/–) with p53/MCA sarcomas received control GpC dinucleotides with 0 Gy (black, n = 9), CpG ODN alone (green, n = 17), control GpC dinucleotides with 20 Gy (blue, n = 17), or CpG ODN with 20 Gy (red, n = 18). Figure shows time to tumor quintupling (days). (D) Heterozygous mice (Rag2+/–;yc+ or Rag2+/–;yc+/–) with p53/MCA sarcomas received control GpC dinucleotides with 0 Gy (black, n = 9), CpG ODN alone (green, n = 17), control GpC dinucleotides with 20 Gy (blue, n = 17), or CpG ODN with 20 Gy (red, n = 18). Figure shows time to tumor quintupling (days). (E) Homozygous mice (Rag2–/–;yc– or Rag2–/–;yc–/–) with p53/MCA sarcomas received GpC dinucleotides control with 0 Gy (black, n = 14), CpG ODN alone (green, n = 12), GpC dinucleotides control with 20 Gy (blue, n = 12), or CpG ODN with 20 Gy (red, n = 12). Figure shows time to tumor quintupling (days). (F) Homozygous mice (Rag2–/–;yc– or Rag2–/–;yc–/–) with p53/MCA sarcomas received GpC dinucleotides control with 0 Gy (black, n = 14), CpG ODN alone (green, n = 12), GpC dinucleotides control with 20 Gy (blue, n = 12), or CpG ODN with 20 Gy (red, n = 12). Figure shows time to tumor quintupling (days). Kruskal-Wallis test was used for the group comparison, while the Wilcoxon test was selected for the pair-wise comparisons. ***P ≤ 0.001, ****P ≤ 0.0001.

Figure 7 CD8 T cells are required for the treatment effects of CpG+RT.

(A) Primary sarcoma initiation by intramuscular injection of Adeno-Cas9-sgp53 and MCA. Autochthonous sarcoma develops at the injection site about 7–11 weeks after induction. Mice were treated with CpG ODN or control GpC dinucleotides and 0 or 20 Gy when tumors reached > 70 mm3. Mice received i.p. CD8 isotype control or CD8 depletion Ab on the same day tumors received RT. CD8 isotype control or CD8 depletion Ab are repeated every 3.5 days until tumor size reached humane endpoint. (B) 129/SvJ mice with p53/MCA sarcomas, injected with CD8 isotype control Ab, received GpC dinucleotides control with 0 Gy (black, n = 13), CpG ODN alone (green, n = 12), GpC dinucleotides control with 20 Gy (blue, n = 15), or CpG ODN with 20 Gy (red, n = 14). (C) 129/SvJ mice with p53/MCA sarcomas, injected with CD8 isotype control Ab, received GpC dinucleotides control with 0 Gy (black, n = 13), CpG ODN alone (green, n = 12), GpC dinucleotides control with 20 Gy (blue, n = 15), or CpG ODN with 20 Gy (red, n = 14). (D) 129/SvJ mice with p53/MCA sarcomas, injected with CD8 depleting Ab, received GpC dinucleotides control with 0 Gy (black, n = 16), CpG ODN alone (green, n = 14), GpC dinucleotides control with 20 Gy (blue, n = 13), or CpG ODN with 20 Gy (red, n = 11). (E) 129/SvJ mice with p53/MCA sarcomas, injected with CD8 depletion Ab, received GpC dinucleotides control with 0 Gy (black, n = 16), CpG ODN alone (green, n = 14), GpC dinucleotides control with 20 Gy (blue, n = 13), or CpG ODN with 20 Gy (red, n = 11). Figure shows time to tumor quintupling (days). Kruskal-Wallis test was used for the group comparison, while the Wilcoxon test was selected for the pair-wise comparisons. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Conflict of interest: DGK is a cofounder of Xrad Therapeutics, which is developing radiosensitizers, and serves on the Scientific Advisory Board of Lumicell, which is commercializing intraoperative imaging technology. DGK is a coinventor on patents for radiosensitizers and an intraoperative imaging device. DGK also receives funding for a clinical trial from a Stand Up To Cancer (SU2C) Catalyst Research Grant with support from Merck. The laboratory of DGK received funding from Xrad Therapeutics, Merck, and Bristol-Myers Squibb, but this did not support the research described in this manuscript. DGK received funding from Varian Medical Systems and an antibody to OX-40 from Bristol-Myers Squibb, which were used to support experiments in this manuscript.

Copyright: © 2024, Su et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: JCI Insight. 2024;9(14):e178767.https://doi.org/10.1172/jci.insight.178767.
==== Refs
1 Ayodele O Razak ARA Immunotherapy in soft-tissue sarcoma Curr Oncol 2020 27 suppl 1 17 23 10.3747/co.27.5407 32174754
2 Karavasilis V et al Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer 2008 112 7 1585 1591 10.1002/cncr.23332 18278813
3 Ribas A Wolchok JD Cancer immunotherapy using checkpoint blockade Science 2018 359 6382 1350 1355 10.1126/science.aar4060 29567705
4 Tawbi HA et al Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Lancet Oncol 2017 18 11 1493 1501 10.1016/S1470-2045(17)30624-1 28988646
5 Demetri GD et al Soft tissue sarcoma clinical practice guidelines in oncology J Natl Compr Canc Netw 2005 3 2 158 194 19817028
6 Katz D et al More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments Am Soc Clin Oncol Educ Book 2018 38 925 938 10.1200/EDBK_205423 30231352
7 Stone HB et al Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma J Natl Cancer Inst 1979 63 5 1229 1235 291749
8 Zebertavage LK et al Transcriptional upregulation of NLRC5 by radiation drives STING- and interferon-independent MHC-I expression on cancer cells and T cell cytotoxicity Sci Rep 2020 10 1 7376 10.1038/s41598-020-64408-3 32355214
9 Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 4 252 264 10.1038/nrc3239 22437870
10 Huang J et al Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma Nat Commun 2017 8 15999 10.1038/ncomms15999 28691711
11 Lee C-L et al Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma JCI Insight 2019 4 13 e128698 10.1172/jci.insight.128698 31112524
12 Wisdom AJ et al Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy Nat Commun 2020 11 1 6410 10.1038/s41467-020-19917-0 33335088
13 Castle KD et al Genetically engineered mouse models for studying radiation biology Transl Cancer Res 2017 6 suppl 5 S900 S913 10.21037/tcr.2017.06.19 30733931
14 Spitzer MH Nolan GP Mass cytometry: single cells, many features Cell 2016 165 4 780 791 10.1016/j.cell.2016.04.019 27153492
15 Hao Y et al Integrated analysis of multimodal single-cell data Cell 2021 184 13 3573 3587 10.1016/j.cell.2021.04.048 34062119
16 Swanson BJ et al RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR-dependent process Immunity 2002 17 5 605 615 10.1016/S1074-7613(02)00456-9 12433367
17 Hänninen A et al Ly6C supports preferential homing of central memory CD8+ T cells into lymph nodes Eur J Immunol 2011 41 3 634 644 10.1002/eji.201040760 21308682
18 Connolly KA et al A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response Sci Immunol 2021 6 64 eabg7836 10.1126/sciimmunol.abg7836 34597124
19 Wang B et al CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell J Immunother Cancer 2021 9 8 e003100 10.1136/jitc-2021-003100 34462326
20 Mabrouk N et al CXCR6 expressing T cells: functions and role in the control of tumors Front Immunol 2022 13 1022136 10.3389/fimmu.2022.1022136 36311728
21 Di Pilato M et al CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment Cell 2021 184 17 4512 4530 10.1016/j.cell.2021.07.015 34343496
22 Wherry EJ Kurachi M Molecular and cellular insights into T cell exhaustion Nat Rev Immunol 2015 15 8 486 499 10.1038/nri3862 26205583
23 Nielsen CF et al Topoisomerase IIα is essential for maintenance of mitotic chromosome structure Proc Natl Acad Sci U S A 2020 117 22 12131 12142 10.1073/pnas.2001760117 32414923
24 Gil-Kulik P et al Potential involvement of BIRC5 in maintaining pluripotency and cell differentiation of human stem cells Oxid Med Cell Longev 2019 2019 8727925 10.1155/2019/1027106 30774747
25 Milner JJ et al Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours Nature 2017 552 7684 253 257 10.1038/nature24993 29211713
26 Chen J et al Research into the characteristic molecules significantly affecting liver cancer immunotherapy Front Immunol 2023 14 1029427 10.3389/fimmu.2023.1029427 36860864
27 Zhang E-D et al STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation World J Surg Oncol 2022 20 1 301 10.1186/s12957-022-02768-y 36127700
28 Muri J et al The thioredoxin-1 system is essential for fueling DNA synthesis during T-cell metabolic reprogramming and proliferation Nat Commun 2018 9 1 1851 10.1038/s41467-018-04274-w 29749372
29 Jabbar S et al Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor Exp Hematol Oncol 2022 11 1 83 10.1186/s40164-022-00329-3 36316713
30 Yang H-Q et al Single-cell TCR sequencing reveals the dynamics of T cell repertoire profiling during Pneumocystis infection Front Microbiol 2021 12 637500 10.3389/fmicb.2021.637500 33959105
31 Medler TR et al Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help Sci Rep 2023 13 1 6277 10.1038/s41598-023-33508-1 37072485
32 Eckelhart E et al A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development Blood 2011 117 5 1565 1573 10.1182/blood-2010-06-291633 21127177
33 Frank MJ et al In Situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma Cancer Discov 2018 8 10 1258 1269 10.1158/2159-8290.CD-18-0743 30154192
34 Liu Y et al Single-cell profiling reveals divergent, globally patterned immune responses in murine skin inflammation iScience 2020 23 10 101582 10.1016/j.isci.2020.101582 33205009
35 van der Weyden CA et al Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions Blood Cancer J 2017 7 9 e603 10.1038/bcj.2017.85 28885612
36 Benechet AP et al T cell–intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection Proc Natl Acad Sci U S A 2016 113 8 2182 2187 10.1073/pnas.1516485113 26862175
37 Bjorkdahl O et al Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues Immunology 2003 110 2 170 179 10.1046/j.1365-2567.2003.01727.x 14511230
38 Keshavarz Valian H et al CCR7+ central and CCR7- effector memory CD4+ T cells in human cutaneous leishmaniasis J Clin Immunol 2013 33 1 220 234 10.1007/s10875-012-9788-7 22990666
39 Steinke FC et al TCF-1 and LEF-1 act upstream of Th-POK to promote the CD4(+) T cell fate and interact with Runx3 to silence Cd4 in CD8(+) T cells Nat Immunol 2014 15 7 646 656 10.1038/ni.2897 24836425
40 Xing S et al Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity Nat Immunol 2016 17 6 695 703 10.1038/ni.3456 27111144
41 Samji T Khanna KM Understanding memory CD8+ T cells Immunol Lett 2017 185 32 39 10.1016/j.imlet.2017.02.012 28274794
42 Newman AM et al Determining cell type abundance and expression from bulk tissues with digital cytometry Nat Biotechnol 2019 37 7 773 782 10.1038/s41587-019-0114-2 31061481
43 Petitprez F et al B cells are associated with survival and immunotherapy response in sarcoma Nature 2020 577 7791 556 560 10.1038/s41586-019-1906-8 31942077
44 Sagiv-Barfi I et al Eradication of spontaneous malignancy by local immunotherapy Sci Transl Med 2018 10 426 eaan4488 10.1126/scitranslmed.aan4488 29386357
45 Cheng S et al A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells Cell 2021 184 3 792 809 10.1016/j.cell.2021.01.010 33545035
46 Villani A-C et al Single-cell RNA-Seq reveals new types of human blood dendritic cells, monocytes, and progenitors Science 2017 356 6335 eaah4573 10.1126/science.aah4573 28428369
47 Ye Y et al Plasmacytoid dendritic cell biology and its role in immune-mediated diseases Clin Transl Immunology 2020 9 5 e1139 10.1002/cti2.1139 32489664
48 Rawat K et al CCL5-producing migratory dendritic cells guide CCR5+ monocytes into the draining lymph nodes J Exp Med 2023 220 6 e20222129 10.1084/jem.20222129 36946983
49 Liu J et al Dendritic cell migration in inflammation and immunity Cell Mol Immunol 2021 18 11 2461 2471 10.1038/s41423-021-00726-4 34302064
50 Woo MLS et al Calcium channel β3 subunit regulates ATP-dependent migration of dendritic cells Sci Adv 2023 9 38 eadh1653 10.1126/sciadv.adh1653 37729408
51 Miyahara Y et al Toll-like receptor 9-positive plasmacytoid dendritic cells promote Th17 immune responses in oral lichen planus stimulated by epithelium-derived cathepsin K Sci Rep 2023 13 1 19320 10.1038/s41598-023-46090-3 37935734
52 Curreli S et al Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions J Biol Chem 2007 282 42 30346 30356 10.1074/jbc.M702965200 17699524
53 Schellenburg S et al Role of neuropilin-2 in the immune system Mol Immunol 2017 90 239 244 10.1016/j.molimm.2017.08.010 28843905
54 Merad M et al The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting Annu Rev Immunol 2013 31 563 604 10.1146/annurev-immunol-020711-074950 23516985
55 Tanaka Y et al Oral CD103-CD11b+ classical dendritic cells present sublingual antigen and induce Foxp3+ regulatory T cells in draining lymph nodes Mucosal Immunol 2017 10 1 79 90 10.1038/mi.2016.46 27166558
56 Omatsu M et al THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer Nat Commun 2023 14 1 5534 10.1038/s41467-023-41095-y 37749092
57 Kamijo H et al Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47 Leukemia 2019 34 3 845 856 10.1038/s41375-019-0622-6 31712778
58 Zhang X et al Upregulation of THBS1 is related to immunity and chemotherapy resistance in gastric cancer Int J Gen Med 2021 14 4945 4957 10.2147/IJGM.S329208 34475782
59 Stirling ER et al Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response J Immunother Cancer 2022 10 11 e004712 10.1136/jitc-2022-004712 36418073
60 Alberts B, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. T Cells and MHC Proteins. https://www.ncbi.nlm.nih.gov/books/NBK26926/
61 Dhatchinamoorthy K et al Cancer immune evasion through loss of MHC class I antigen presentation Front Immunol 2021 12 636568 10.3389/fimmu.2021.636568 33767702
62 Leone P et al MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells J Natl Cancer Inst 2013 105 16 1172 1187 10.1093/jnci/djt184 23852952
63 Mueller A et al CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3 J Leukoc Biol 2008 83 4 875 882 10.1189/jlb.1006645 18174362
64 Korniejewska A et al Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes Immunology 2011 132 4 503 515 10.1111/j.1365-2567.2010.03384.x 21255008
65 Chow MT et al Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti–PD-1 therapy Immunity 2019 50 6 1498 1512 10.1016/j.immuni.2019.04.010 31097342
66 Tokunaga R et al CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy Cancer Treat Rev 2018 63 40 47 10.1016/j.ctrv.2017.11.007 29207310
67 Xiao W et al The CXCL10/CXCR3 pathway contributes to the synergy of thermal ablation and PD-1 blockade therapy against tumors Cancers (Basel) 2023 15 5 1427 10.3390/cancers15051427 36900218
68 Günther J et al Limitations and off-target effects of tryptophan-related IDO Inhibitors in cancer treatment Front Immunol 2019 10 1801 10.3389/fimmu.2019.01801 31417567
69 Luke JJ et al Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors J Clin Oncol 2018 36 16 1611 1618 10.1200/JCO.2017.76.2229 29437535
70 Nacev BA et al Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets Nat Commun 2022 13 1 3405 10.1038/s41467-022-30453-x 35705560
71 Cancer Genome Atlas Research Network Comprehensive and integrated genomic characterization of adult soft tissue sarcomas Cell 2017 171 4 950 965 10.1016/j.cell.2017.10.014 29100075
72 Seo YD et al Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: A phase 1 nonrandomized controlled trial JAMA Oncol 2023 9 12 1660 1668 10.1001/jamaoncol.2023.4015 37824131
73 What fraction of mRNA transcripts are captured per cell? 10X Genomics. https://kb.10xgenomics.com/hc/en-us/articles/360001539051-What-fraction-of-mRNA-transcripts-are-captured-per-cell Accessed June 19, 2024
74 mRNA Extraction. Qiagen. https://www.qiagen.com/zh-us/product-categories/discovery-and-translational-research/dna-rna-purification/rna-purification/mrna Accessed June 19, 2024
75 Otsuka T et al CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study BMC Cancer 2022 22 1 744 10.1186/s12885-022-09818-4 35799134
76 Zhang Z et al CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials Pharmaceutics 2021 14 1 73 10.3390/pharmaceutics12010016 35056969
77 Bodenheimer T, et al. FastPG: Fast clustering of millions of single cells [preprint]. 10.1101/2020.06.19.159749 Posted on bioRxiv July 21, 2020
78 Patro R et al Salmon provides fast and bias-aware quantification of transcript expression Nat Methods 2017 14 4 417 419 10.1038/nmeth.4197 28263959
79 Dobin A et al STAR: ultrafast universal RNA-Seq aligner Bioinformatics 2013 29 1 15 21 10.1093/bioinformatics/bts635 23104886
80 Picard Tools - By Broad Institute - GitHub Pages. https://broadinstitute.github.io/picard/ Accessed June 19, 2024
81 Durinck S et al Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt Nat Protoc 2009 4 8 1184 1191 10.1038/nprot.2009.97 19617889
82 Newman AM et al Robust enumeration of cell subsets from tissue expression profiles Nat Methods 2015 12 5 453 457 10.1038/nmeth.3337 25822800
83 Gu Z et al Complex heatmaps reveal patterns and correlations in multidimensional genomic data Bioinformatics 2016 32 18 2847 2849 10.1093/bioinformatics/btw313 27207943
84 Becht E et al Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression Genome Biol 2016 17 1 218 10.1186/s13059-016-1070-5 27765066
85 Song L et al TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-Seq data Nat Methods 2021 18 6 627 630 10.1038/s41592-021-01142-2 33986545
86 Selitsky SR et al Prognostic value of B cells in cutaneous melanoma Genome Med 2019 11 1 36 10.1186/s13073-019-0647-5 31138334
87 Sims JS et al Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire Proc Natl Acad Sci U S A 2016 113 25 E3529 E3537 10.1073/pnas.1601012113 27261081
88 Butler A et al Integrating single-cell transcriptomic data across different conditions, technologies, and species Nat Biotechnol 2018 36 5 411 420 10.1038/nbt.4096 29608179
89 Bais AS Kostka D scds: computational annotation of doublets in single-cell RNA sequencing data Bioinformatics 2019 36 4 1150 1158 10.1093/bioinformatics/btz698 31501871
90 Yang S et al Decontamination of ambient RNA in single-cell RNA-Seq with DecontX Genome Biol 2020 21 1 57 10.1186/s13059-020-1950-6 32138770
91 Aran D et al Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage Nat Immunol 2019 20 2 163 172 10.1038/s41590-018-0276-y 30643263
92 Korsunsky I et al Fast, sensitive and accurate integration of single-cell data with Harmony Nat Methods 2019 16 12 1289 1296 10.1038/s41592-019-0619-0 31740819
93 Andreatta M et al Interpretation of T cell states from single-cell transcriptomics data using reference atlases Nat Commun 2021 12 1 2965 10.1038/s41467-021-23324-4 34017005
